{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}],"title":"Participants alive after 18 months from start of treatment who received HCT."},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"title":"Participants alive after 18months from start of treatment who did not receive HCT."},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"title":"Participants deceased after 18 months from start of treatment who received HCT."},{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"}],"title":"Participants deceased after 18 months from start of treatment who did not receive HCT."}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"The total length of follow-up will be 18 months from the start of treatment (day 1). Four categories were added for participants alive 18 months from start of treatment (day 1) 1) Participants alive after 18 months from start of treatment who received hematopoietic cell transplantation (HCT); 2) Participants alive after 18months from start of treatment who did not receive HCT.; 3) Participants deceased after 18 months from start of treatment who received HCT; 4) Participants deceased after 18 months from start of treatment who did not receive HCT.","groups":[{"description":"Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine (AZC): Given IV or SC\n\nDecitabine: Given IV or SC\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm A (Decitabine or Azacitidine)"},{"description":"Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm B (Induction-like Chemotherapy Regimen)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 18 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}